** Shares of eye drugmaker Eyenovia Inc EYEN.O rise 3.4%
to 92 cents premarket
** Co says it has started a process to explore strategic
alternatives, including potential sale of assets, a sale of the
co, a merger, or other strategic action
** Plans further development of its potential multi-billion
dollar product called MicroPine for pediatric progressive myopia
or nearsightedness
** EYEN expects to report interim study results testing
MicroPine in Q4 and plans to file for marketing approval in 2025
** Up to last close, stock has fallen 57.2% YTD
(Reporting by Sneha S K in Bengaluru)
((Sneha.SK@thomsonreuters.com;))